Emerging insights into inflammation-driven atherosclerosis: immune cell mechanisms

• by Abdullahi Osman Mohamud, Zhiyin Dai

• July 2, 2026

Clinical correlates of lipoprotein (a) and apolipoprotein B levels in patients with dyslipidemia and cardiovascular disease

• by Luana Alexandrescu, Daria Maria Alexandrescu, Ionut Tiberiu Tofolean, Doina Ecaterina Tofolean, Steliana Pindichi, Eugen Dumitru, Bogdan Campineanu, Cristina Aftenie, Andreea Nelson Twakor, Alexandra Herlo, Elena Rusu, Diana Raluca Baicu, Madalina Ilie, Filip-Vasile Berariu, Laura Maria Condur

• July 9, 2026

Development and validation of a deep neural network for predicting coronary heart disease in hypertensive patients using 24-hour ambulatory blood pressure monitoring: a retrospective study

• by Li Wang, Ji Song, Yingzhu Xie, Yaqi Liu, Liangbang Zeng

• July 15, 2026

FDA Approves First Oral PCSK9 Inhibitor

Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.

• by Kathryn Wighton

• July 16, 2026

• 2 min